As of 2026-02-17, the Intrinsic Value of Immunovant Inc (IMVT) is -13.25 USD. This IMVT valuation is based on the model Peter Lynch Fair Value. With the current market price of 25.75 USD, the upside of Immunovant Inc is -151.46%.
Based on its market price of 25.75 USD and our intrinsic valuation, Immunovant Inc (IMVT) is overvalued by 151.46%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -13.25 - -13.25 | -13.25 | -151.46% |
| P/E | (38.01) - (51.47) | (47.18) | -283.2% |
| DDM - Stable | (16.10) - (46.04) | (31.07) | -220.7% |
| DDM - Multi | (0.23) - (0.49) | (0.31) | -101.2% |
| Market Cap (mil) | 4,513.46 |
| Beta | 1.18 |
| Outstanding shares (mil) | 175.28 |
| Enterprise Value (mil) | 3,991.59 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.35% |
| Cost of Debt | 5.00% |
| WACC | 8.67% |